Effects of Two-by-Two Combination Therapy with Valproic Acid, Lithium Chloride, and Celecoxib on the Angiogenesis of the Chicken Chorioallantoic Membrane

Ehsan Afzal1, MSc; Sedigheh Alinezhad2, PharmD; Marjan Khorsand1, MSc; Mohammad Javad Khoshnood2, PhD; Mohammad Ali Takhshid1, PhD

1Diagnostic Laboratory Sciences and Technology Research Center, Paramedical School, Shiraz University of Medical Sciences, Shiraz, Iran; 2School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence: Mohammad Ali Takhshid, PhD; Diagnostic Laboratory Sciences and Technology Research Center, Paramedical School, Meshkinfam Street, Shiraz, Iran
Tel/Fax: +98 71 32289113
Email: takhshidma@sums.ac.ir
Received: 5 March 2017
Revised: 15 July 2017
Accepted: 6 August 2017

Abstract

Background: The synergistic effects of valproic acid (VPA), lithium (Li), and celecoxib (CX) have been shown in combination therapy against the proliferation and metastasis of numerous cancers. Angiogenesis plays a critical role in the pathogenesis of tumor growth and metastasis. The aim of the present study was to evaluate the antiangiogenic effects of VPA, lithium chloride (LiCl), and CX, alone or in 2-by-2 combinations, using the chicken chorioallantoic membrane (CAM) assay.

Methods: Fertilized chicken eggs were randomly divided into 10 groups: control, VPA (1.8 and 3.6 µmol/CAM), Li (0.15 and 0.60 µmol/CAM), CX (0.02 and 0.08 µmol/CAM), VPA+Li, VPA+CX, and CX+Li (n=10 per group). A window was made on the eggshells and the CAMs were exposed to a filter disk containing VPA, LiCl, and CX, alone or in 2-by-2 combinations. The control CAMs were treated with distilled water (vehicle). Three days after the treatment, the number of vessel branch points was counted in each CAM. The data were analyzed using SPSS, version 15. One-way ANOVA, followed by the Tukey tests, was used to compare the groups. A P<0.05 was considered a statistically significant difference between the groups.

Results: According to the results, all the tested drugs decreased the number of the vessel branch points in a dose-dependent manner compared to the control group (P<0.001). In addition, combinations of the drugs were more effective in decreasing angiogenesis than the use of each drug alone.

Conclusion: These findings suggest that 2-by-2 combinations of VPA, CX, and LiCl can be considered an effective antiangiogenesis therapeutic modality.

Keywords: Angiogenesis inhibitors ● Combined modality therapy ● Valproic acid ● Celecoxib ● Lithium chloride

Introduction

Angiogenesis is a physiological process whereby new blood vessels sprout from the preexisting ones. This complex process is controlled via an appropriate balance between angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and angiogenin1 and antiangiogenic...
Synergistic effects of valproate, lithium, and celecoxib on angiogenesis

Factors such as thrombospondin-1, endostatin, and angiostatin. Angiogenesis is a necessary step in several physiological conditions, including embryogenesis, wound healing, and reconstruction of the uterine endometrium during the menstrual cycle. Nonetheless, unregulated angiogenesis is involved in the pathogenesis of several diseases, including tumor growth and metastasis. Antiangiogenesis therapy has, thus, emerged as a new therapeutic opportunity for the treatment of cancer. In this context, several antiangiogenesis drugs such as monoclonal antibody against human VEGF (bevacizumab; Avastin) and tyrosine kinase inhibitors (sunitinib and erlotinib) have been introduced. Nevertheless, not only have most of these drugs demonstrated several side effects but also they have shown limited benefits when used in monotherapy regimens owing to the heterogenic entities of tumors and the induction of drug resistance. Combination therapy, in which 2 or more drugs with different mechanisms are used concurrently for the treatment of a disease, has attracted great attention in this context because it both decreases the toxic side effects arising from the use of high doses of a drug and increases the efficiency of the treatment due to the additive effects that occur between the drugs via different mechanisms.

Valproic acid (VPA), lithium (Li), and celecoxib (CX) are among antiproliferative and antimetastastic drugs used in several combination therapies against numerous cancers. The major concern in this context, especially for Li, is the well-known adverse effects of these drugs on several organs, including the kidney, thyroid, and parathyroid. It has, however, been demonstrated that minimizing the dose of Li can ameliorate such adverse effects for patients.

Targeting different molecular pathways that are commonly involved in carcinogenesis, low cost, and ease of use make them good candidates for combination therapy. VPA-mediated tumor suppression is mostly exerted through two mechanisms including inhibition of histone deacetylase (HDAC) and regulation of Notch signaling, while the antitumor effects of Li and CX are believed to be mediated through the inhibition of glycogen synthase kinase3β (GSK3β) and cyclooxygenase-2 (COX-2), respectively. In addition to antiproliferative impacts, the antiangiogenic effects of these drugs have been indicated in some previous studies. For example, the association between an increased expression of COX-2 and tumor angiogenesis and the antiangiogenic effects of COX-2 inhibition by CX, mediated through the inhibition of VEGF expression, has been previously demonstrated. In the case of Li, in a recent study, Maeng et al. reported the anti-lymphangiogenic effects of Li via the inhibition of GSK3β. The antiangiogenic effects of HDAC inhibition by VPA or other HDAC inhibitors, mediated through the inhibition of VEGF expression, have also been demonstrated in several studies.

Although the synergistic effects of CX, Li, and VPA in tumor cell proliferation and metastasis have been investigated in previous studies, to the best of our knowledge, the possible synergistic effects of CX, Li, and VPA on angiogenesis have yet to be fully elucidated. To that end, in the current study, we treated chorioallantoic membranes (CAMs) with different concentrations of CX, Li, and VPA, alone or in 2-by-2 combinations, and counted the number of vessel branch points (as an index of angiogenesis). The CAM assay is a valid and reliable method commonly used for the evaluation of angiogenesis. The aim of the present preliminary study was to evaluate the antiangiogenic effects of VPA, lithium chloride (LiCl), and CX, alone or in combinations, using the CAM assay.

Materials and Methods

Control and Experimental Groups
Fertilized chicken eggs (purchased from the Department of Poultry, School of Veterinary Medicine, Shiraz University) on day 10 of embryo development were incubated at 37 °C and 50% humidity with automatic rotation in an incubation system. The eggs were randomly divided into a control group and 9 experimental groups (n=10 per group). The experimental groups were comprised of the VPA-treated groups (1.8 and 3.6 μmol/CAM), LiCl-treated groups (0.15 and 0.60 μmol/CAM), CX-treated groups (0.02 and 0.08 μmol/CAM), VPA+LiCl-treated group (3.6+0.60 μmol/CAM, respectively), VPA+CX-treated group (3.6+0.08 μmol/CAM, respectively), and CX+LiCl-treated group (0.08+0.60 μmol/CAM, respectively). Stock solutions of VPA (120 and 240 mM) and LiCl (10 and 40 mM) were prepared in sterile distilled water. The CX stock solution (1.34 and 3.64 mM) was prepared in dimethyl sulfoxide (DMSO) 0.1%. The control group was treated with a vehicle, including sterile distilled water or DMSO 0.1%, which had no significant effects on angiogenesis. Next, 15 µL of the stock solution or the vehicle was loaded on sterile methylcellulose (DMSO) 0.1%. The control group was treated with the vehicle. All the chemicals and drugs were purchased from Sigma-Aldrich (St. Louis, MO, USA).
CAM Assay
On day 10 of embryo development, a 1.0 cm² square window was made in the eggshells under sterile condition and the sterile methylcellulose discs, which were loaded with the stock solution or the vehicle, were applied on the CAMs. The drug-treated eggs were incubated at 37 °C and 50% humidity for 72 hours. On day 13 of embryo development, the CAM tissues were removed under filter discs, rinsed in phosphate-buffered saline, and photographed (150X) using a stereomicroscope (Leica Zoom 2000).

Digital Image Analysis
CAM angiogenesis was microscopically evaluated through the quantification of the total number of the vessel branch points using computer-assisted image analysis software (Wimasis Image Analysis). Moreover, the total number of the vessel branch points of a selected area (area under the disc=1 cm²) was counted (figure 1A). An example of the measurement of the total number of the vessel branch points with digital image analysis is depicted in figure 1B. The validity and reliability of the digital image analysis were tested by comparing the results with those obtained from manual counting of the total number of vessel branch points by a person, who was blinded to the treatments.

Statistical Analysis
The effects of the drugs on CAM angiogenesis were expressed as the total number of the vessel branch points. The data were analyzed using SPSS software (version 16). The Kolmogorov–Smirnov test was used to check the normal distribution of the data. Because the data from the total number of the vessel branch points were normally distributed (P=0.2), one-way ANOVA, followed by the Tukey post hoc test, was employed to compare the mean of the total number of the vessel branch points between the different groups. All the results were reported as mean±SD of at least 10 CAMs. A P<0.05 was considered a statistically significant difference between the groups.

Results
Effects of VPA on CAM angiogenesis
The CAMs were exposed to VPA-containing disks (1.8 and 3.6 µmol/CAM) to evaluate the effects of VPA on CAM angiogenesis by counting the number of the vessel branch points, as an index of angiogenesis. As can be seen in figure 2B and figure C, the vessels were irregular and brittle. In addition, a significant decrease in the number of the vessel branch points compared to the control CAMs (figure 2A) (P<0.001) was observed upon the treatment of the CAMs with VPA in a dose-dependent manner (figure 2D).

Effects of LiCl on CAM Angiogenesis
LiCl-containing disks (0.15 and 0.60 µmol/CAM) were applied on the CAMs, and the number of the vessel branch points was counted. As is
demonstrated in the micrographs of figure 3, the number of the vessel branch points was significantly lowered in the LiCl-treated CAMs compared to the control CAMs. Comparison of the mean vessel number between the control and LiCl-treated CAMs (one-way ANOVA, followed by the Tukey post hoc test) revealed a significant dose-dependent decrease in the number of the vessel branch points in the LiCl-treated group (P<0.001).

Effects of CX on CAM Angiogenesis
The CAMs in the CX group were exposed to CX-containing disks (0.02 and 0.08 µmol/CAM) for 3 days, and the number of the vessel branch points was counted. The micrographs in figure 4 demonstrate the number of the vessel branch points in the control and CX-treated groups. CX treatment lowered the number of the vessel branch points in a dose-dependent manner by comparison with the control CAMs (P<0.001) (one-way ANOVA, followed by the Tukey post hoc test).

Synergistic Effects of VPA, LiCl, and CX on CAM Angiogenesis
The CAMs were treated with 2-by-2 combinations of the drugs: CX (0.08 µmol/CAM)+VPA (3.6 µmol/CAM), CX (0.08 µmol/CAM)+LiCl (0.60 µmol/CAM), and LiCl (0.60 µmol/CAM)+VPA (3.6 µmol/CAM) for 3 days. Thereafter, the number of the vessel branch points was counted. The micrographs in figure 5 demonstrate the number of the vessel branch points in the CAMs treated with the combinations of the drugs. Our findings showed that combination therapy decreased the number of the vessel branch points in comparison to the control CAMs (P<0.001) and monotherapy with each of the aforementioned drugs alone (P<0.001) (one-way ANOVA, followed by the Tukey post hoc test).

Discussion
In the present study, we applied a widely used in vivo angiogenesis model, CAM assay, to...
evaluate the effects of VPA, Li, and CX alone or in 2-by-2 combinations on angiogenesis. Our findings showed that all 3 drugs reduced the number of vessel branch points as a marker of angiogenesis. When using the 2-by-2 combinations of the drugs, we observed more efficient antiangiogenic effects, which suggested possible additive effects between the antiangiogenic effects of VPA, Li, and CX. Given the role of angiogenesis in the pathogenesis of several diseases such as rheumatoid arthritis, atherosclerosis, diabetic nephropathy and retinopathy, endometriosis, and especially tumor growth and metastasis and on the other hand the side effects of the current antiangiogenesis therapy including anti-VEGF antibodies and tyrosine kinase inhibitors, a combinational therapeutic regimen using VPA, Li, and CX can be considered for the prevention and treatment of such diseases.

Because cancer development is a complex multistep process initiated with cell proliferation and extended with angiogenesis and metastasis, it is vitally important that an anticancer agent capable of targeting all these aspects of carcinogenesis simultaneously be identified. The antiproliferative and antimetastatic impacts of COX-2, HDAC, and GSK3 inhibitors have been clearly demonstrated in a large number of studies conducted on numerous kinds of tumors. Furthermore, these inhibitors exhibit synergistic effects when used concurrently for the treatment of tumors. For instance, it has been demonstrated that combined treatment with VPA and CX induces more apoptosis in neuroblastoma cells than individual drug treatment. Moreover, combination therapy with LiCl and VPA decreases growth via apoptosis in medullary thyroid cancer cells and carcinoid tumor cells in vitro.

Besides its anti-inflammatory effects, CX is reported to exhibit antiproliferative and antimetastatic effects in many tumor cells. In the present study, we found significant and dose-dependent effects of CX at low concentrations in the inhibition of angiogenesis in the CAM assay. Decrease in the expression of angiogenic factors such as angiopoietin-2, VEGF, and bFGF may be a description for the antiangiogenic effects of CX. The antiangiogenic effects of CX are also demonstrated in combination therapy. For instance, combined inhibitory effects of CX and curcumin have been reported on the angiogenesis of the CAM. El-sayed et al. recently revealed the anti-inflammatory and antiangiogenic effects of CX with evening primrose oil co-treatment in complete Freund's adjuvant-induced arthritis in rats. Furthermore, a combination of CX and octreotide was found to reduce intrahepatic and splanchic angiogenesis via downregulation in hypoxia-inducible factor-1α-VEGF signaling pathways.

Historically, VPA and Li have been known as effective drugs for the treatment of neurological disorders such as bipolar disorder. The synergistic effects of VPA and Li, mediated through the inhibition of GSK3 activity, have also been demonstrated for the treatment of drug-resistant bipolar patients and in glutamate-induced neurotoxicity. Aside from neurological effects, the role of GSK3 and HDAC has been explored in the pathogenesis of cancer, which is why the use of VPA and Li for the treatment and prevention of cancers has been considered. In the present study, we evaluated the effects of Li and VPA alone or in combination with each other or with CX on CAM angiogenesis. Based on our finding, Li and VPA suppressed CAM angiogenesis in a dose-dependent manner. The antiangiogenesis activity of VPA, observed in our study, is consistent with a previous study reported by Michaelis et al., who used a similar CAM assay model and demonstrated that VPA inhibited angiogenesis. The inhibitory effects of VPA on vessel formation have also been shown using other angiogenesis models, including the zebrafish model, in vitro Matrigel plug assay,
and mouse model.\textsuperscript{26} In the current study, we observed maximum inhibitory effects on angiogenesis when using combinations of the drugs. The exact molecular mechanisms underlying the antiangiogenic effects of Li and VPA and their synergistic effects are not clear. Even so, downregulation in angiogenesis factors, including VEGF, VEGF receptor, and FGF, by VPA and Li may be an explanation for their antiangiogenic properties.\textsuperscript{24,26} As was discussed previously, the synergism between the neuroprotective effects of VPA and Li has been attributed to their inhibitory impacts on GSK activity.\textsuperscript{34} Whether or not such a mechanism is involved in the synergistic effects of VPA with Li in the present study remains to be elucidated in future studies.

The present study has 2 major limitations. At first glance, our data demonstrated that the combination of the drugs exerted greater, if not comparable, effects than the sum of the individual effects, suggesting the superiority of combination therapy to monotherapy. Nevertheless, further pharmacological evaluations such isobologram analysis\textsuperscript{38} are needed to determine the exact interaction of the drugs. In addition, in the CAM assay, we measured the toxicity of the drugs by evaluating the effects of the drugs on the viability of the embryos.\textsuperscript{29} All the embryos in our drug-treated groups were alive during the study period, suggesting that the concentrations of the drugs used in our study (both in monotherapy or combination therapy) had no toxic effects. Nonetheless, more in vivo studies are required to determine and compare the side effects of the drugs in combination or in monotherapy.

**Conclusion**

Our findings showed that a combined low dose of CX, Li, and VPA synergistically inhibited angiogenesis in the CAM. Therefore, 2-by-2 combinations of these drugs may have beneficial implications for the treatment of cancer and other pathological conditions closely related to angiogenesis. Our findings are, however, preliminary and further studies drawing upon other in vitro and in vivo techniques of angiogenesis are needed to confirm our data and to understand the mechanisms of the synergistic effects of the drugs.

**Acknowledgment**

This manuscript was extracted from the PharmD thesis of Sedigheh Alinezhad and was supported by a grant from the Vice-Chancellor for Research Affairs of Shiraz University of Medical Sciences. We are also grateful to all the staff of the Diagnostic Laboratory Sciences and Technology Research Center for their technical assistance in this work.

**Conflict of Interest:** None declared.

**References**

1. Ribatti D. The discovery of angiogenic growth factors: the contribution of Italian scientists. Vasc Cell. 2014;6:8. doi: 10.1186/2045-824X-6-8. PubMed PMID: 24690161; PubMed Central PMCID: PMCPMC3974417.
2. Yadav L, Puri N, Rastogi V, Satpute P, Sharma V. Tumour Angiogenesis and Angiogenic Inhibitors: A Review. J Clin Diagn Res. 2015;9:XE01-XE5. doi: 10.7860/JCDR/2015/12016.6135. PubMed PMID: 26266204; PubMed Central PMCID: PMCPMC4525594.
3. Craig MP, Sumanas S. ETS transcription factors in embryonic vascular development. Angiogenesis. 2016;19:275-85. doi: 10.1007/s10456-016-9511-z. PubMed PMID: 27126901; PubMed Central PMCID: PMCPMC4937796.
4. Yoshitomi Y, Ikeda T, Saito H, Yoshitake Y, Ishigaki Y, Hatta T, et al. JunB regulates angiogenesis and neurovascular parallel alignment in mouse embryonic skin. J Cell Sci. 2017;130:916-26. doi: 10.1242/jcs.196303. PubMed PMID: 28096474.
5. Gonzalez AC, Costa TF, Andrade ZA, Medrado AR. Wound healing - A literature review. An Bras Dermatol. 2016;91:614-20. doi:10.1590/abd1806-4841.20164741. PubMed PMID: 27828635; PubMed Central PMCID: PMCPMC5087220.
6. Maruyama T, Yoshimura Y. Molecular and cellular mechanisms for differentiation and regeneration of the uterine endometrium. Endocr J. 2008;55:795-810. PubMed PMID: 18580040.
7. Kasiotis KM, Tzanetou EN, Haroutounian SA. Pyrazoles as potential anti-angiogenesis agents: a contemporary overview. Front Chem. 2014;2:78. doi: 10.3389/fchem.2014.00078. PubMed PMID: 25250310; PubMed Central PMCID: PMCPMC4158875.
8. Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R, et al. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. Eur J Cancer. 2017;75:245-58. doi: 10.1016/j.ejca.2017.01.026. PubMed
9. Abbosh PH, McConkey DJ, Plimack ER. Targeting Signaling Transduction Pathways in Bladder Cancer. Curr Oncol Rep. 2015;17:58. doi: 10.1007/s11912-015-0477-6. PubMed PMID: 26472299.

10. Giordani E, Zoratto F, Strudel M, Papa A, Rossi L, Minozzi M, et al. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment. Curr Cancer Drug Targets. 2016;16:175-85. PubMed PMID: 26278713.

11. Fujita KI, Ishida H, Kubota Y, Sasaki Y. Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology. Curr Drug Metab. 2017;18:186-98. doi: 10.2174/1389200218666170105165832. PubMed PMID: 28059038.

12. Stuhler V, Bedke J. Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity. BMC Med. 2016;14:201. doi: 10.1186/s12916-016-0754-8. PubMed PMID: 27923360; PubMed Central PMCID: PMCPMC5141635.

13. Gotink KJ, Rovithi M, de Haas RR, Honeywell RJ, Dekker H, Poel D, et al. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr). 2016;38:119-29. doi: 10.1007/s13402-015-0218-8. PubMed PMID: 25665527; PubMed Central PMCID: PMCPMC4555235.

14. Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011;103:1222-6. doi: 10.1093/jnci/djr246. PubMed PMID: 21765011; PubMed Central PMCID: PMCPMC4415086.

15. Cincarova L, Zdrahal Z, Fajkus J. New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs. 2013;22:1535-47. doi: 10.1517/13543784.2013.853037. PubMed PMID: 24160174.

16. Gao JH, Wen SL, Feng S, Yang WJ, Lu YY, Tong H, et al. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis. 2016;19:501-11. doi: 10.1007/s10456-016-0952-9. PubMed PMID: 27380212; PubMed Central PMCID: PMCPMC5026725.

17. El-Sayed RM, Moustafa YM, El-Azab MF. Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. Inflammopharmacology. 2014;22:305-17. doi: 10.1007/s10787-014-0200-5. PubMed PMID: 24664592.

18. Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4:27. doi: 10.1186/s40345-016-0068-y. PubMed PMID: 27900734; PubMed Central PMCID: PMCPMC5164879.

19. Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T, et al. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. Anticancer Res. 2017;37:35-46. doi: 10.21873/anticancerres.11286. PubMed PMID: 28011471.

20. Kuwano T, Nakao S, Yamamoto H, Tsenyoshi M, Yamamoto T, Kuwano M, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 2004;18:300-10. doi: 10.1096/fj.03-0473com. PubMed PMID: 14769824.

21. Liu N, Chen L, Cai N. Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Int J Clin Exp Pathol. 2015;8:4990-8. PubMed PMID: 26191192; PubMed Central PMCID: PMCPMC4503064.

22. Wang L, Chen W, Xie X, He Y, Bai X. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp Oncol. 2008;30:42-51. PubMed PMID: 18438340.

23. Maeng YS, Lee R, Lee B, Choi SI, Kim EK. Lithium inhibits tumor lymphangiogenesis and metastasis through the inhibition of TGFBIp expression in cancer cells. Sci Rep. 2016;6:20739. doi: 10.1038/srep20739. PubMed PMID: 26857144; PubMed Central PMCID: PMCPMC4746585.

24. Zhao Y, You W, Zheng J, Chi Y, Tang W, Du R. Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1alpha/VEGF signals. Clin Transl Oncol. 2016;18:1123-30. doi: 10.1007/s12094-016-1494-0. PubMed PMID: 26942921.

25. Ribatti D. The chick embryo chorioallantoic membrane (CAM). A multifaceted experimental model. Mech Dev. 2016;141:70-7. doi: 10.1016/j.mod.2016.05.003. PubMed PMID: 27178379.

26. Zhang ZH, Hao CL, Liu P, Tian X, Wang LH, Zhao L, et al. Valproic acid inhibits tumor angiogenesis in mice
transplanted with Kasumi1 leukemia cells. Mol Med Rep. 2014;9:443-9. doi: 10.3892/mmr.2013.1834. PubMed PMID: 24297248; PubMed Central PMCID: PMC3896514.

27. Bisht M, Dhasmana DC, Bist SS. Angiogenesis: Future of pharmacological modulation. Indian J Pharmacol. 2010;42:2-8. doi: 10.4103/0253-7613.62395. PubMed PMID: 24297248; PubMed Central PMCID: PMCPMC3896514.

28. Chen Y, Tsai YH, Tseng SH. Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells. Anticancer Res. 2011;31:2231-9. PubMed PMID: 21737646.

29. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res. 2010;159:640-4. doi: 10.1016/j.jss.2008.08.004. PubMed PMID: 19394967; PubMed Central PMCID: PMCPMC2858235.

30. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol. 2009;16:481-6. doi: 10.1245/s10434-008-0194-6. PubMed PMID: 19030935; PubMed Central PMCID: PMCPMC2740795.

31. Wang J, Wu K, Bai F, Zhai H, Xie H, Du Y, et al. Celecoxib could reverse the hypoxia-induced Angiopoietin-2 upregulation in gastric cancer. Cancer Lett. 2006;242:20-7. doi: 10.1016/j.canlet.2005.10.030. PubMed PMID: 16338068.

32. Zuo CH, Li ZR, Zhou X, Ouyang YZ, Zhou ZY, Zeng L. Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice. Ai Zhong. 2006;25:414-20. PubMed PMID: 16613672.

33. Mandracchia D, Tripodo G, Trapani A, Ruggieri S, Annese T, Chilpanidas T, et al. Inulin based micelles loaded with curcumin or celecoxib with effective anti-angiogenic activity. Eur J Pharm Sci. 2016;93:141-6. doi: 10.1016/j.ejps.2016.08.027. PubMed PMID: 27539141.

34. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci. 2008;28:2576-88. doi: 10.1523/JNEUROSCI.5467-07.2008. PubMed PMID: 18322101; PubMed Central PMCID: PMCPMC5241911.

35. Huang RY, Hsieh KP, Huang WW, Yang YH. Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study. Br J Psychiatry. 2016;209:393-9. doi: 10.1192/bjp.bp.116.181362. PubMed PMID: 27388574.

36. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, et al. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol. 2004;65:520-7. doi: 10.1124/mol.65.3.520. PubMed PMID: 14978230.

37. Farooq M, El-Faham A, Khattab SN, Elkayal AM, Ibrahim MF, Taha NA, et al. Biological screening of novel derivatives of valproic acid for anticancer and antiangiogenic properties. Asian Pac J Cancer Prev. 2014;15:7785-92. PubMed PMID: 25292064.

38. Grabovsky Y, Tallarida RJ. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther. 2004;304:310:981-6. doi: 10.1124/jpet.104.067264. PubMed PMID: 15175417.

39. Kue CS, Tan KY, Lam ML, Lee HB. Chick embryo chorioallantoic membrane (CAM): an alternative predictive model in acute toxicological studies for anti-cancer drugs. Exp Anim. 2015;64:129-38. doi: 10.1538/expanim.14-0059. PubMed PMID: 25736707; PubMed Central PMCID: PMCPMC4427727.